Fig. 3. ZA protected bone area and suppressed tumor growth in vossicles.

Vossicle and collagen matrices were implanted with luciferase-positive ACE-1 prostate cancer cells (100,000 cells per implant) and placed subcutaneously into athymic mice. ZA or vehicle was administered 7-days later and BLI imaging recorded weekly. (a) Trabecular bone area in tibia per tissue area was significantly greater in ZA-treated mice (n=8, *p<0.05). (b) Serum TRAP5b (osteoclast marker) was significantly decreased with ZA treatment (n=8, *p<0.05). (c) Vossicle bone area per tumor area was higher in the ZA group (n=8, *p<0.05). (d) Tumor area was reduced in vossicles from the ZA group. (e) ZA-treated vossicles had lower luciferase activity (n=8, 10⁹p/sec/cm²/Sr, *p<0.05 versus veh-vossicle, **p<0.05 versus veh-collagen) than vehicle-treated vossicles. (f-g) Vossicles in ZA-treated groups had more bone (Mason’s Trichrome mineralized tissue blue). (h-i) TRAP5b staining showed reduced osteoclast numbers in ZA-treated mice (j-k) H&E staining revealed no morphological differences in collagen implanted tumor treated with ZA or vehicle.